Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.

J Chao; E Buxo; A Cervantes; F Dayyani; CMSR Lima; Richard Greil; HWM Van Laarhoven; S Lorenzen; V Heinemann; R Kischel; K Shitara; F Lordick

Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.

J Chao, E Buxo, A Cervantes, F Dayyani, CMSR Lima, Richard Greil, HWM Van Laarhoven, S Lorenzen, V Heinemann, R Kischel, K Shitara, F Lordick

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	38
Issue number	15
Publication status	Published - 2020
Event	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - ELECTR NETWORK Duration: 29 May 2020 → 31 May 2020

Cite this

Chao, J., Buxo, E., Cervantes, A., Dayyani, F., Lima, CMSR., Greil, R., Van Laarhoven, HWM., Lorenzen, S., Heinemann, V., Kischel, R., Shitara, K., & Lordick, F. (2020). Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. JOURNAL OF CLINICAL ONCOLOGY , 38(15).

Chao, J ; Buxo, E ; Cervantes, A et al. / Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. In: JOURNAL OF CLINICAL ONCOLOGY 2020 ; Vol. 38, No. 15.

@article{12fea2fa2b8a441ea8c483fa4b85300e,

title = "Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.",

author = "J Chao and E Buxo and A Cervantes and F Dayyani and CMSR Lima and Richard Greil and {Van Laarhoven}, HWM and S Lorenzen and V Heinemann and R Kischel and K Shitara and F Lordick",

year = "2020",

language = "English",

volume = "38",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 29-05-2020 Through 31-05-2020",

}

Chao, J, Buxo, E, Cervantes, A, Dayyani, F, Lima, CMSR, Greil, R, Van Laarhoven, HWM, Lorenzen, S, Heinemann, V, Kischel, R, Shitara, K & Lordick, F 2020, 'Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.', JOURNAL OF CLINICAL ONCOLOGY , vol. 38, no. 15.

Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. / Chao, J; Buxo, E; Cervantes, A et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 38, No. 15, 2020.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.

AU - Chao, J

AU - Buxo, E

AU - Cervantes, A

AU - Dayyani, F

AU - Lima, CMSR

AU - Greil, Richard

AU - Van Laarhoven, HWM

AU - Lorenzen, S

AU - Heinemann, V

AU - Kischel, R

AU - Shitara, K

AU - Lordick, F

PY - 2020

Y1 - 2020

M3 - Abstract (Journal)

SN - 0732-183X

VL - 38

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Y2 - 29 May 2020 through 31 May 2020

ER -

Chao J, Buxo E, Cervantes A, Dayyani F, Lima CMSR, Greil R et al. Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. JOURNAL OF CLINICAL ONCOLOGY . 2020;38(15).